S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

NextCure Stock Price, Forecast & Analysis (NASDAQ:NXTC)

$37.75
+0.34 (+0.91 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$34.69
Now: $37.75
$38.43
50-Day Range
$25.43
MA: $35.03
$82.89
52-Week Range
$13.86
Now: $37.75
$109.00
Volume575,600 shs
Average Volume204,432 shs
Market Capitalization$857.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$857.49 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.


NextCure (NASDAQ:NXTC) Frequently Asked Questions

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The business earned $1.58 million during the quarter, compared to analysts' expectations of $1.50 million. View NextCure's Earnings History.

When is NextCure's next earnings date?

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for NextCure.

What price target have analysts set for NXTC?

3 equities research analysts have issued 12-month price objectives for NextCure's stock. Their forecasts range from $52.00 to $95.00. On average, they anticipate NextCure's share price to reach $78.67 in the next twelve months. This suggests a possible upside of 108.4% from the stock's current price. View Analyst Price Targets for NextCure.

What is the consensus analysts' recommendation for NextCure?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Has NextCure been receiving favorable news coverage?

Headlines about NXTC stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NextCure earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for NextCure.

Are investors shorting NextCure?

NextCure saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 515,300 shares, an increase of 6.9% from the September 15th total of 482,000 shares. Based on an average daily trading volume, of 88,400 shares, the short-interest ratio is currently 5.8 days. Currently, 4.2% of the company's shares are short sold. View NextCure's Current Options Chain.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Biogen (BIIB), Adobe (ADBE), Lam Research (LRCX), NVIDIA (NVDA), Roku (ROKU), Chipotle Mexican Grill (CMG), Advanced Micro Devices (AMD), Amkor Technology (AMKR), Amarin (AMRN) and Anika Therapeutics (ANIK).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

When did the company's lock-up period expire?

NextCure's lock-up period expired on Tuesday, November 5th. NextCure had issued 5,000,000 shares in its public offering on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are NextCure's major shareholders?

NextCure's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (1.84%) and Strs Ohio (0.03%). Company insiders that own NextCure stock include Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

Which major investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC. View Insider Buying and Selling for NextCure.

Which major investors are buying NextCure stock?

NXTC stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought NextCure stock in the last two years include Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $37.75.

How big of a company is NextCure?

NextCure has a market capitalization of $857.49 million. View Additional Information About NextCure.

What is NextCure's official website?

The official website for NextCure is http://www.nextcure.com/.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]


MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel